The Influence of Oncogenic RAS on Chemotherapy and Radiotherapy Resistance Through DNA Repair Pathways

Abstract

RAS oncogenes are chief tumorigenic drivers, and their mutation constitutes a universal predictor of poor outcome and treatment resistance. Despite more than 30 years of intensive research since the identification of the first RAS mutation, most attempts to therapeutically target RAS mutants have failed to reach the clinic. In fact, the first mutant RAS inhibitor, Sotorasib, was only approved by the FDA until 2021. However, since Sotorasib targets the KRAS G12C mutant with high specificity, relatively few patients will benefit from this therapy. On the other hand, indirect approaches to inhibit the RAS pathway have revealed very intricate cascades involving feedback loops impossible to overcome with currently available therapies. Some of these mechanisms play different roles along the multistep carcinogenic process. For instance, although mutant RAS increases replicative, metabolic and oxidative stress, adaptive responses alleviate these conditions to preserve cellular survival and avoid the onset of oncogene-induced senescence during tumorigenesis. The resulting rewiring of cellular mechanisms involves the DNA damage response and pathways associated with oxidative stress, which are co-opted by cancer cells to promote survival, proliferation, and chemo- and radioresistance. Nonetheless, these systems become so crucial to cancer cells that they can be exploited as specific tumor vulnerabilities. Here, we discuss key aspects of RAS biology and detail some of the mechanisms that mediate chemo- and radiotherapy resistance of mutant RAS cancers through the DNA repair pathways. We also discuss recent progress in therapeutic RAS targeting and propose future directions for the field.

Long noncoding RNA BBOX1-AS1 increased radiotherapy sensitivity in colorectal cancer by stabilizing and activating PFK1

“…However, the effect of BBOX1-AS1 on radiotherapy sensitivity in CRC cells is unknown. It is well known that radiotherapy resistance often leads to a poor response to therapy [ 27 , 28 ]. Therefore, our findings provide novel ideas for the clinical treatment of radiotherapy resistance.…”

KRAS in NSCLC: State of the Art and Future Perspectives

“…Preclinical data demonstrated that KRAS mutations might induce chemo and radio-resistance via multiple mechanisms, such as the induction of senescence, imbalance in ROS production, and activation of mechanisms of DNA repair [ 127 ]. Importantly, resistance to radiation has also been demonstrated in some clinical reports [ 81 ].…”

Cancer cell genetics shaping of the tumor microenvironment reveals myeloid cell-centric exploitable vulnerabilities in hepatocellular carcinoma

“…Patients with heightened MAPK/ERK activity exhibited increased numbers of CD204 + positive cells, which identifies macrophages with pro-tumorigenic functions 67,68 . In contrast, MYC-overexpressing patients showed increased infiltration of S1009 + immunosuppressive myeloid cells 69,70 . Thus, these results provide further evidence of the distinct impact Myc and MAPK/ERK exert on myeloid cell education, which correlated with poor patient prognosis (Fig.…”